((自动化翻译由路透提供，请见免责声明 ))
10月4日 - ** 癌症测试制造商Exact Sciences 的股价盘前上涨1.2%至67.22美元
** 该公司称，美国食品和药物管理局（FDA）批准了 (link) 其名为 "Cologuard Plus "的粪便 DNA 检测，用于筛查结肠直肠癌。
** EXAS称，新检测方法可减少假阳性筛查的可能性，从而最大限度地减少不必要的后续结肠镜检查。
** 大肠癌发生在结肠或直肠，它们是大肠的一部分
** 截至上一交易日收盘，股价累计下跌 10.2
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.